Abstract:Ferroptosis is an iron-dependent form of programmed cell death, which plays crucial roles in tumorigenesis, ischemia–reperfusion injury and various human degenerative diseases. Ferroptosis is characterized by aberrant iron and lipid metabolisms. Mechanistically, excess of catalytic iron is capable of triggering lipid peroxidation followed by Fenton reaction to induce ferroptosis. The induction of ferroptosis can be inhibited by sufficient glutathione (GSH) synthesis via system Xc – transporter-mediated cystine uptake. Therefore, induction of ferroptosis by inhibition of cystine uptake or dampening of GSH synthesis has been considered as a novel strategy for cancer therapy, while reversal of ferroptotic effect is able to delay progression of diverse disorders, such as cardiopathy, steatohepatitis, and acute kidney injury. The ubiquitin (Ub)–proteasome pathway (UPP) dominates the majority of intracellular protein degradation by coupling Ub molecules to the lysine residues of protein substrate, which is subsequently recognized by the 26S proteasome for degradation. Ubiquitination is crucially involved in a variety of physiological and pathological processes. Modulation of ubiquitination system has been exhibited to be a potential strategy for cancer treatment. Currently, more and more emerged evidence has demonstrated that ubiquitous modification is involved in ferroptosis and dominates the vulnerability to ferroptosis in multiple types of cancer. In this review, we will summarize the current findings of ferroptosis surrounding the viewpoint of ubiquitination regulation. Furthermore, we also highlight the potential effect of ubiquitination modulation on the perspective of ferroptosis-targeted cancer therapy.

DUBbing Ferroptosis in Cancer Cells

Targeting Ferroptosis in Breast Cancer

Regulation of Ferroptosis Pathway by Ubiquitination

The DUBA-SLC7A11-c-Myc axis is critical for stemness and ferroptosis

Ferroptosis in life: To be or not to be

Broad Spectrum Deubiquitinase Inhibition Induces Both Apoptosis and Ferroptosis in Cancer Cells

Deubiquitinase USP35 modulates ferroptosis in lung cancer via targeting ferroportin

Ferroptosis is Governed by Differential Regulation of Transcription in Liver Cancer

Ferroptosis: A double-edged sword

The deubiquitinase ZRANB1 is an E3 ubiquitin ligase for SLC7A11 and regulates ferroptotic resistance

Protein modification and degradation in ferroptosis

Roles of ferroptosis in urologic malignancies

Ferroptosis as a potential target for cancer therapy

Understanding the unique mechanism of ferroptosis: a promising therapeutic target

Ferroptosis as a new tool for tumor suppression through lipid peroxidation

Ferroptosis as a novel form of regulated cell death: Implications in the pathogenesis, oncometabolism and treatment of human cancer

Autophagy-Dependent Ferroptosis in Cancer

Understanding the mechanistic regulation of ferroptosis in cancer: the gene matters

The transcription factor HBP1 promotes ferroptosis in tumor cells by regulating the UHRF1-CDO1 axis

Ferroptosis and its emerging role in tumor

Advances in ferroptosis of cancer therapy